Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused Patients with Lower-Risk MDS Who Are Not Responding to Or Are Ineligible for ESA
Findings from the IMerge study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Findings from the IMerge study
Evidence for efficacy is based on the results from the DeFi study
Positive opinion was adopted for the treatment of patients aged one year and older
Findings from the CodeBreaK 300 study
Findings from a phase II study
Findings from a phase II non-randomised controlled study in patients with high-risk oral proliferative verrucous leukoplakia
New indication concerns a combination with gemcitabine and cisplatin in first-line treatment
Updated indication restricts the use to patients whose tumours express PD-L1 CPS ≥ 1 as determined by an FDA-approved test
Findings from the FLAURA2 study
Findings from the European MCL Elderly study
New indications concerns a combination with enzalutamide for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated
Findings from the TAB study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.